150 related articles for article (PubMed ID: 36036309)
1. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma.
Rudman Y; Duskin-Bitan H; Masri-Iraqi H; Akirov A; Shimon I
Pituitary; 2022 Dec; 25(6):882-890. PubMed ID: 36036309
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
3. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
[TBL] [Abstract][Full Text] [Related]
4. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
5. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
Rudman Y; Duskin-Bitan H; Manisterski Y; Pertzov B; Akirov A; Masri-Iraqi H; Shimon I
Clin Endocrinol (Oxf); 2021 Oct; 95(4):606-617. PubMed ID: 34160838
[TBL] [Abstract][Full Text] [Related]
6. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
Kim D; Ku CR; Kim K; Jung H; Lee EJ
Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
[TBL] [Abstract][Full Text] [Related]
7. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
8. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
Shimon I; Benbassat C; Tzvetov G; Grozinsky-Glasberg S
Pituitary; 2011 Mar; 14(1):11-5. PubMed ID: 20717729
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
10. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
11. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
12. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
13. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
15. Male prolactinomas presenting with normal testosterone levels.
Shimon I; Benbassat C
Pituitary; 2014 Jun; 17(3):246-50. PubMed ID: 23756784
[TBL] [Abstract][Full Text] [Related]
16. The factors associated with the persistence of hypogonadism in male patients with prolactinoma.
Piskinpasa H; Turgut S
Neuro Endocrinol Lett; 2022 Sep; 43(3):154-160. PubMed ID: 36179726
[TBL] [Abstract][Full Text] [Related]
17. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
19. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
Ribeiro RS; Abucham J
Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
